Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). (Q33391803)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Rafael Fonseca

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S. Vincent Rajkumar

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

3

M A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

8

J A Lust

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

M Q Lacy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

21

F Buadi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

10

D Dingli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

S R Hayman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

K D Short

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Kumar

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

P R Greipp

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S J Russell

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Zeldenrust

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

P L Bergsagel

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

V Roy

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J R Mikhael

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

A K Stewart

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

K Laumann

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J B Allred

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S J Mandrekar

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

9 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1934-1939

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

13 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

International uniform response criteria for multiple myeloma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

IMiDs: a novel class of immunomodulators

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

Thalidomide is an inhibitor of angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2978257

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.190

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.190

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.190

Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.190

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.190

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.190

Novel therapies for multiple myeloma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20827286

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20827286

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20827286%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

20827286

1 reference